BACKGROUND
The use of the ring-substituted amphetamine derivative ±3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') has escalateed to epidemic proportions in recent years. Several experimental studies indicate that MDMA damages brain serotonin (5-HT) in animals (including nonhuman primates) and possibly humans and that a significant proportion of users may eventually be at risk for long--term neurotoxicological effects, particularly in the hippocampus, a brain region that is believed to play an important role in learning and the consolidation of new memories [1] [2] [3] . Accordingly, a neuropsychological literature has begun to emerge where human studies suggest that repeated use of MDMA produces lasting impairments in explicit memory [4] [5] [6] [7] [8] [9] [10] .
That is, users of MDMA have been found to be impaired on neuropsychological measures of memory that require the conscious recollection of an episode (see [11] ). For example, Bolla et al, [4] compared abstinent MDMA users and control subjects on the Rey-Auditory Verbal Learning Test (RAVLT; [12] ), the Wechsler Memory Scale-Revised (WMS; [13] ) and the Rey-Osterrieth Complex Figure (see [12] ). They found that greater use of MDMA (in terms of total milligrams per month) was associated with greater impairments in immediate verbal memory and delayed visual memory. Moreover, Morgan [6] utilized subtests of the Rivermead Behavioral Memory Test (RBMT; [14] ) to investigate immediate and delayed recall. He found MDMA users to recall significantly fewer ideas from a short passage of prose that was read out to subjects immediately after its presentation and after a delay. Moreover, Zakzanis and Young [15] examined the neurotoxic potential of continued MDMA use in humans and its functional consequences over the course of 1--year. They also found that continued use of MDMA is associated with progressive decline in terms of immediate and delayed recall on the RBMT. In addition, Parrot et al [8] , administered a computerized battery of cognitive tasks and found MDMA users to recall significantly fewer words immediately following presentation and after a delay. Krystal et al [16] , also found a pattern of mild-to-moderate impairment in terms of both initial and delayed recall on the Logical Memory subtest of the WMS-R in chronic MDMA users.
Indeed, evidence supporting an impairment of explicit memory in abstinent MDMA users is plentiful. Given that memory is not a unitary system, however, and that many different neuropsychological processes are likely to influence performance on memory measures, researchers have begun to elucidate the specificity memory impairment in this population. For example, Gouzoulis-Mayfrank et al [17] , state that although the nature of cognitive disturbance in MDMA users is not clear, an impairment of working memory might be the common denominator underlying or contributing to declines of performance in various tasks. Accordingly, they showed that MDMA users were unimpaired in simple tests of attention and were, however, impaired in more complex tests of attention, in memory and learning tasks, and in tasks reflecting aspects of general intelligence. Moreover, McCann et al [5] found MDMA users to manifest significant performance deficits on a sustained attention task requiring arithmetic calculations, a task requiring complex attention and incidental learning, a task requiring short term memory and a task of semantic recognition and verbal reasoning. Finally, Morgan [6] established the presence of elevated impulsivity with recreational use of MDMA in a series of two studies using a behavioral measure of impulsivity, spatial span, 'Tower of London' tests, and an impulsiveness, venturesomness and empathy questionnaire.
Direct behavioral evidence of this sort in MDMA users prompted researchers to elucidate further the contribution of higher order executive function on the neuropsychological deficits found in abstinent MDMA users. For example, Semple et al [18] used the CANTAB Spatial Working Memory subtest, Trial Making Test (Part B), phonemic word fluency, and the Stroop task to examine executive function in abstinent MDMA users. It was found that larger lifetime doses of MDMA were associated with more errors on the Spatial Working Memory test. As such, it was concluded that this finding might indicate that decreased performance on this particular Spatial Working Memory test may be attributed to the high density of MDMA destroyed serotonin terminals found in the frontal lobes. From this finding, it remains unclear however, how the frontal-executive system can be implicated in keeping with inferences made from a spatial working memory test and the absence of a meaningful difference between MDMA users and non-users on the remaining measures of executive function. That is, while working memory provides temporary storage to hold data on-line for brief periods (up to 10-15 seconds), the temporal integration of behavior entails the ability to organize ones perceptions and actions. The prefrontal cortex acts in a supervisory capacity upon the hippocampal episodic memory system, thereby directing attention in the temporal domain. One may view different episodic memories as being 'called-up' into working memory, as each in turn is made the focus of current attention. Hence, working memory is a multi-component system that loops beyond frontal cortices (see [19] ). Thus, the validity of an executive deficit in abstinent MDMA users remains unclear as deficits in working memory do not always implicate deficiencies in executive function, but may reflect disturbances anywhere along the phonological loop in keeping with the working memory model proposed by Baddely and Hitch [20] .
To determine the nature of executive function in MDMA users that might further address questions of specificity with regard to the neurotoxic potential of continued MDMA use in humans and its functional consequences, we administered an ecologically valid battery of executive measures to a sample of abstinent MDMA users and a control group of non-MDMA users. Accordingly, the purpose of this investigation was to further explore the nature and pattern of executive function in abstinent MDMA users.
MATERIAL AND METHODS

Participants
Twenty-four MDMA users participated in the study. All participants were recruited by word of mouth and hence, self referred, having learned about ongoing research on the consequences of MDMA use. Subjects were all fluent English speaking individuals. Exclusion from the study was warranted when subjects reported a past or current history of major medical illness (e.g, neurologic, renal, endocrine, or hematologic), current major psychiatric illness as determined by the Structured Clinical Interview of the Diagnostic Statistical Manual-III-Revised, a positive drug screen for illicit or prescribed psychoactive drugs, or current alcohol dependence. Subjects were also excluded if they reported a current pregnancy, migraine, dyslexia, or eating disorder. Most participants, however, reported erratic, or highly erratic sleep habits typically coinciding with MDMA use. Hence, given that sleep deprivation is a noted finding in MDMA users and affects cognitive performance, we tested participants when they reported at least 7-nights of 7-9 hours of continuous sleep. Moreover, all subjects agreed to abstain from all drugs for at least 2-weeks prior to testing. Their drug free status was confirmed by urine and blood drug screens. Given that the half--life of MDMA in animals is 1 to 2 hours, the 2--week period of abstinence was deemed long enough to rule out any withdrawal effects including sleep deprivation.
Twenty-four non-MDMA users served as a control group. These subjects were also all fluent English speaking individuals without a self-reported past or current history of major medical illness (e.g., neurologic, renal, endocrine, or hematologic), current major psychiatric illness, or alcohol dependence. Control subjects were also excluded if they reported a current pregnancy, migraine, dyslexia, or eating disorder. Both MDMA users and controls were not paid for their time but were reimbursed for travel (i.e., parking) expenses. Informed consent was obtained from all participants.
Sociodemographic data of the participants is presented in Table 1 . Most MDMA users were female (67%) and had completed approximately 15 years of education. The modal age of the MDMA users was 23-years. The non-MDMA users were on average 20 years of age and had completed approximately 14 years of education. Sixty-seven percent of the control group was female.
Age of participants differed significantly between groups. Accordingly, all statistical analyses were carried out with age as a covariate. There were no other statistically significant differences between groups in terms of sociodemographic variables.
Procedure
Participants completed a brief survey to determine their characteristic MDMA use and other recreational drug experience. Participants also completed the Behavioral Assessment of Dysexecutive Syndrome (BADS; 21) Briefly, the BADS is a test battery aimed at predicting everyday problems arising from the 'Dysexecutive Syndrome' which can be characterized by an amorphous, varied group of deficits resulting from diverse aetiologies, different locations, and variable extents of abnormalities [21] . BADS measures included (in the order they were administered): ber of tasks attempted, whether the rule was broken, and the maximum amount of time spent on any one subtask.
Once the scoring of each test was completed, raw scores were converted to profile scores that ranged from 0-4. The six profile scores were then added together, resulting in a Total Profile Score.
RESULTS
MDMA and other drug use
To provide an estimate of the intensity, frequency, and duration of MDMA use, detailed information about prior MDMA use was obtained from a structured interview that ascertained the number of milligrams per capsule of MDMA generally taken at one time (each capsule was assumed to equal 100 mg based on previously published estimates; see Bolla et al. [4] ), the number of times that MDMA was taken per month, and the total number of months of MDMA use. A dose variable -a combination of intensity and frequency -was also calculated by multiplying the self-reported milligrams ingested in a single MDMA session (which could last hours and involve several separate doses of MDMA) by the number of MDMA sessions per month [4] . Table 2 summarizes the characteristics of MDMA use in the user group. Table 3 illustrates the other recreational drug exposure in the MDMA user and non-user groups.
Statistical analyses between groups
Using age as a covariate, between group differences on the BADS was examined using ANCOVA. Additionally, the magnitude of effect was articulated using Cohen's [22] effect size statistic and associated overlap distribution percentages (see [23] ). Briefly, an effect size was used to describe the magnitude of difference between group means, rather than the mere chance probability of the difference. That is, statistical significance testing does not reveal the strength of effect, whereas an effect size is a direct measure of magnitude where an effect size of:
• 0.0 reflects no difference in mean scores;
• an effect size of about 0.2 represents a small effect; • 0.5 a medium effect, and, • 0.8 a large effect; in keeping with Cohen's [22] rule of thumb. Moreover, Cohen's effect size can be easily transformed into overlap percentages that illustrate the degree to which test scores overlap between groups. For example, if an effect size of 0.5 is found, approximately 67% of the two groups being compared share the same test scores. Only 33% differ in terms of performance on the measure. Hence, the less overlap, the greater the effect size, or more po-
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Significant differences between groups emerged on the Temporal Judgment Test, Modified Six Elements Test, and Total Profile Score (see Table 4 ). The associated effect sizes on these particular subtests ranged from medium to large in keeping with Cohen's [22] heuristic benchmark. Moreover, the most discriminatory measure was the Modified Six Elements Test, as approximately 58% of MDMA user scores fell below the lowest score obtained by a non-user (i.e., 42% overlap in test score distribution).
Significant moderators of effect
Pearson product moment correlations were calculated between MDMA user sociodemographic characteristics and each BADS component. A number of sociodemographic variables correlated significantly with BADS subtest scores. 
DISCUSSION
The purpose of this investigation was to determine the nature of executive function in MDMA users that might further address questions of specificity with regard to the neurotoxic potential of continued MDMA use in humans and its functional consequences. Our results indicate that for this sample of users, MDMA may be associated with deficits in terms of executive function. That is, we found evidence of impairment on the Temporal Judgment and Modified Six Elements subtests of the BADS, and more convincingly, depressed scores on all but one subtest of the BADS in MDMA users, resulting in a significant Total Profile Score between groups. Additionally, an effect size analysis revealed a large difference between the groups on the Modified Six Elements Test and Total Profile Score in terms of test score discriminability. In addition, several significant product moment correlations were found suggesting that increases in MDMA consumption may relate to more pronounced impairment in executive function.
Together, the results basically implicate the alteration of serotonin, or 5-hydroxytryptamine (5-HT) transmission in frontal cortices following MDMA use. This finding underscores evidence that has found neurons that synthesize and release 5-HT to participate in the control of many central cognitive functions, and that alterations of serotoninergic transmission are associated with various neuropsychiatric conditions such as major depressive disorder, anxiety, schizophrenia, and behavioral disorders in dementias, all of which are sometimes marked by executive dysfunction [23] [24] . Indeed, behaviors related to frontal lobe disorders and serotoninergic (5-HT) system abnormalities include impulsivity, depression, obsessive-compulsive characteristics, and retardation, all of which may have contributed to the difference in BADS performance between the two groups in the present investigation.
There were important limitations to the study however. Additional research will have to resolve limitations that impede the validity of most human MDMA research. For instance, given that there is little quality control in street drugs, most investigations provide only an estimate at best when calculating each subjects MDMA intake. As such, for le- gal and ethical reasons, there was no control over MDMA administration nor was there objective confirmation of the dose or purity of MDMA taken.
In keeping with published reports of 'ecstasy' content [25] , however, we were able to deduce that all of our participants had indeed used MDMA in various amounts given the 'type of ecstasy' that was reportedly used. Moreover, published reports (e.g., [25] ) have noted that tablets sold as 'ecstasy' can contain MDA (3,4-methylenedioxy-amphetamine), MDEA (3,4-methylenedioxy-ethylamphetamine), or mixtures of a range of other compounds (e.g., caffeine, ephedrine, selegiline, amphetmaine, ketamine, LSD-9). Although some tablets sold as 'ecstasy' contain little or no MDMA, however, the majority does contain MDMA, or the related compound MDEA [6] .
Another issue concerns the drug history of the participant sample. That is, self-report of drug taking behavior in drug users is notoriously unreliable. As such, it remains unclear whether the reported use of MDMA and other drug exposures are gross under/over estimates of actual drug use. Given that this was a self-referred sample of users with an invested interest in its outcome, it is believed that the self-reported drug taking behaviors of the participants can be loosely described as reliable. It is possible, however, that the executive disturbance may be secondary to polydrug use and not MDMA itself. Indeed, executive type deficits have been found in college students with heavy drinking (e.g. [26] ), marijuana (e.g. [27] ), cocaine (e.g. [28] ), and cocaine/alcohol (e.g. [29] ) histories. Although we excluded MDMA users with a positive drug screen for illicit or prescribed psychoactive drug or current alcohol dependence, the use, but not dependence, of polydrugs use in the MDMA group and its effect on executive function remains quantitatively unresolved and requires further examination. Accordingly, we should emphasize the difficulty of drawing conclusions about the effects of MDMA in poly--drug users. Although we would like to be able to draw neurochemical conclusions based on our observations between groups, given the contamination of the group through use of other substances, and the relative paucity of information regarding the neurochemical effects of MDMA, our desire to relate MDMA use and executive dysfunction should not be taken well beyond what can be foreseeably derived from our preliminary investigation.
Finally, premorbid personality characteristics may also make difficult interpretation of the present findings. That is, poor decision-making and planning, and difficulties in terms of volition and purposive action, might both contribute to substance abuse habit. Accordingly, a person premorbidly marked by poor executive function may be more inclined to abuse MDMA, thus making any cause-effect speculations imperceptible. It will be important for future research to keep these limitations in mind while trying to untangle the neuropsychology of MDMA.
CONCLUSIONS
We have shown here that MDMA use may be associated with deficits in executive function. In keeping with recent neuropsychological investigations of MDMA and its effects on memory, it is possible to reformulate the hypothesized primary consequence of MDMA use in the human brain. That is, it has been speculated that MDMA has an affinity to hippocampal structures based on early investigations of MDMA in rat brains (e.g., [1] [2] ). This led researchers to tentatively conclude that memory impairments in human MDMA users also suffered neuronal damage to hippocampal cortices. We have seen however, a number of MDMA users in our laboratory who do not exhibit a typical mesial-temporal-hippocampal amnestic syndrome following MDMA use. That is, these users do not exhibit the type of memory consolidation deficit found in patients with dementia of the Alzheimer's type, or focal amnesia following stroke. Our users have shown varying deficits in memory that include both prospective and encoding/retrieval difficulties, but not difficulties in the consolidation of new memories. Hence, these types of memory deficits would further support our finding of executive dysfunction in MDMA users in the present study, as it has been found that both prospective memory and encoding/retrieval are negotiated by the frontal lobes (see [30] [31] . Moreover, it is not uncommon to find depressive symptomatology in MDMA users following extensive use [32] . This finding would lend further support to altered executive function in MDMA users as it has been found that the dorsolateral prefrontal cortex, particularly in the right hemisphere, is a key brain structure in emotion/cognition interactions in negative mood states [33] . Hence, what seems to be evolving in the neuropsychology of MDMA, is the consequential role of the frontal--executive system following MDMA use. Future research might want to direct effort toward these cortices to further understand the consequences of MDMA use.
